All patients
corticosteroids: no corticosteroids: yes critical disease severe disease
Immunosuppressants drugs in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
RECOVERY, 2022 0.87 [0.77; 0.98]
Rutgers, 2021 0.59 [0.33; 1.06]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
0.80 [0.63 ; 1.02 ] CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RECOVERY, 2022, Rutgers, 2021, Talaschian, 2021, Veiga, 2021 12 17% 9,561 moderate low deathsdetailed results CORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51]
CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
Declercq J (COV-AID), 2021 1.02 [0.39; 2.66]
EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06]
EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72]
NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31]
NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88]
NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18]
RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37]
RECOVERY, 2021 0.85 [0.76; 0.95]
RECOVERY, 2022 0.87 [0.77; 0.98]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rutgers, 2021 0.62 [0.36; 1.07]
Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.84 [0.78 ; 0.90 ] CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, RECOVERY, 2022, REMAP-CAP (tocilizumab), 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 17 0% 14,863 moderate low deaths (time to event analysis only)detailed results Rutgers, 2021 0.62 [0.36; 1.07]
Talaschian, 2021 1.25 [0.30; 5.14]
0.68 [0.41 ; 1.13 ] Rutgers, 2021, Talaschian, 2021 2 0% 394 moderate not evaluable clinical deteriorationdetailed results CORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86]
Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77]
0.85 [0.59 ; 1.22 ] CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, RCT-TCZ-COVID-19, 2021, Soin AS (COVINTOC), 2021 4 0% 576 moderate not evaluable clinical improvementdetailed results Dongsheng Wang, 2020 2.37 [0.40; 13.96]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
1.65 [1.27 ; 2.16 ] Dongsheng Wang, 2020, REMAP-CAP (tocilizumab), 2021 2 0% 820 moderate not evaluable death or ventilationdetailed results CORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22]
CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
RECOVERY, 2021 0.85 [0.78; 0.93]
RECOVERY, 2022 0.90 [0.81; 0.99]
Rutgers, 2021 0.65 [0.43; 0.99]
Veiga, 2021 1.54 [0.65; 3.63]
0.87 [0.80 ; 0.94 ] CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, RECOVERY, 2021, RECOVERY, 2022, Rutgers, 2021, Veiga, 2021 6 13% 12,217 moderate not evaluable mechanical ventilationdetailed results RCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69]
RECOVERY, 2022 0.87 [0.74; 1.02]
Rutgers, 2021 0.65 [0.35; 1.24]
Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38]
0.87 [0.75 ; 1.01 ] RCT-TCZ-COVID-19, 2021, RECOVERY, 2022, Rutgers, 2021, Soin AS (COVINTOC), 2021 4 0% 8,564 moderate not evaluable ICU admissiondetailed results Rutgers, 2021 0.96 [0.55; 1.68]
Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64]
1.09 [0.71 ; 1.68 ] Rutgers, 2021, Soin AS (COVINTOC), 2021 2 0% 533 moderate not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results Dongsheng Wang, 2020 0.91 [0.02; 47.31]
Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
1.27 [0.70 ; 2.32 ] Dongsheng Wang, 2020, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021 4 0% 410 moderate not evaluable adverse eventsdetailed results Dongsheng Wang, 2020 9.64 [2.76; 33.75]
Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87]
Veiga, 2021 1.65 [0.81; 3.37]
2.47 [1.00 ; 6.10 ] Dongsheng Wang, 2020, Soin AS (COVINTOC), 2021, Veiga, 2021 3 72% 374 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-03 05:56 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526
- roots T: 290
